Search

Your search keyword '"Schwartz, Myron"' showing total 1,487 results
Start Over Author "Schwartz, Myron"
1,487 results on '"Schwartz, Myron"'

9. Intratumoral dendritic cell–CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma

Author

Magen, Assaf, Hamon, Pauline, Fiaschi, Nathalie, Soong, Brian Y., Park, Matthew D., Mattiuz, Raphaël, Humblin, Etienne, Troncoso, Leanna, D’souza, Darwin, Dawson, Travis, Kim, Joel, Hamel, Steven, Buckup, Mark, Chang, Christie, Tabachnikova, Alexandra, Schwartz, Hara, Malissen, Nausicaa, Lavin, Yonit, Soares-Schanoski, Alessandra, Giotti, Bruno, Hegde, Samarth, Ioannou, Giorgio, Gonzalez-Kozlova, Edgar, Hennequin, Clotilde, Le Berichel, Jessica, Zhao, Zhen, Ward, Stephen C., Fiel, Isabel, Kou, Baijun, Dobosz, Michael, Li, Lianjie, Adler, Christina, Ni, Min, Wei, Yi, Wang, Wei, Atwal, Gurinder S., Kundu, Kunal, Cygan, Kamil J., Tsankov, Alexander M., Rahman, Adeeb, Price, Colles, Fernandez, Nicolas, He, Jiang, Gupta, Namita T., Kim-Schulze, Seunghee, Gnjatic, Sacha, Kenigsberg, Ephraim, Deering, Raquel P., Schwartz, Myron, Marron, Thomas U., Thurston, Gavin, Kamphorst, Alice O., and Merad, Miriam

Published
2023
Full Text
View/download PDF

11. Novel Benchmark Values for Open Major Anatomic Liver Resection in Non-cirrhotic Patients: A Multicentric Study of 44 International Expert Centers

Author

Sousa Da Silva, Richard X., Breuer, Eva, Shankar, Sadhana, Kawakatsu, Shoji, Hołówko, Wacław, Santos Coelho, João, Jeddou, Heithem, Sugiura, Teiichi, Ghallab, Mohammed, Da Silva, Doris, Watanabe, Genki, Botea, Florin, Sakai, Nozomu, Addeo, Pietro, Tzedakis, Stylianos, Bartsch, Fabian, Balcer, Kaja, Lim, Chetana, Werey, Fabien, Lopez-Lopez, Victor, Peralta Montero, Luciana, Sanchez Claria, Rodrigo, Leiting, Jennifer, Vachharajani, Neeta, Hopping, Eve, Torres, Orlando J. M., Hirano, Satoshi, Andel, Daan, Hagendoorn, Jeroen, Psica, Alicja, Ravaioli, Matteo, Ahn, Keun Soon, Reese, Tim, Montes, Leonardo A., Gunasekaran, Ganesh, Alcázar, Cándido, Lim, Jin Hong, Haroon, Muhammad, Lu, Qian, Castaldi, Antonio, Orimo, Tatsuya, Moeckli, Beat, Abadía, Teresa, Ruffolo, Luis, Dib Hasan, Josefina, Ratti, Francesca, Kauffmann, Emmanuele F., de Wilde, Roeland F., Polak, Wojciech G., Boggi, Ugo, Aldrighetti, Luca, McCormack, Lucas, Hernandez-Alejandro, Roberto, Serrablo, Alejandro, Toso, Christian, Taketomi, Akinobu, Gugenheim, Jean, Dong, Jiahong, Hanif, Faisal, Park, Joon Seong, Ramia, José M., Schwartz, Myron, Ramisch, Diego, De Oliveira, Michelle L., Oldhafer, Karl J., Kang, Koo Jeong, Cescon, Matteo, Lodge, Peter, Rinkes, Inne H. M. Borel, Noji, Takehiro, Thomson, John-Edwin, Goh, Su Kah, Chapman, William C., Cleary, Sean P., Pekolj, Juan, Regimbeau, Jean-Marc, Scatton, Olivier, Truant, Stéphanie, Lang, Hauke, Fuks, David, Bachellier, Philippe, Ohtsuka, Masayuki, Popescu, Irinel, Hasegawa, Kiyoshi, Lesurtel, Mickaël, Adam, René, Cherqui, Daniel, Uesaka, Katsuhiko, Boudjema, Karim, Pinto-Marques, Hugo, Grąt, Michał, Petrowsky, Henrik, Ebata, Tomoki, Prachalias, Andreas, Robles-Campos, Ricardo, and Clavien, Pierre-Alain

Published
2023
Full Text
View/download PDF

14. Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma

Author

Haber, Philipp K., Castet, Florian, Torres-Martin, Miguel, Andreu-Oller, Carmen, Puigvehí, Marc, Miho, Maeda, Radu, Pompilia, Dufour, Jean-Francois, Verslype, Chris, Zimpel, Carolin, Marquardt, Jens U., Galle, Peter R., Vogel, Arndt, Bathon, Melanie, Meyer, Tim, Labgaa, Ismail, Digklia, Antonia, Roberts, Lewis R., Mohamed Ali, Mohamed A., Mínguez, Beatriz, Citterio, Davide, Mazzaferro, Vincenzo, Finkelmeier, Fabian, Trojan, Jörg, Özdirik, Burcin, Müller, Tobias, Schmelzle, Moritz, Bejjani, Anthony, Sung, Max W., Schwartz, Myron E., Finn, Richard S., Thung, Swan, Villanueva, Augusto, Sia, Daniela, and Llovet, Josep M.

Published
2023
Full Text
View/download PDF

15. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study

Author

Singal, Amit G, Rich, Nicole E, Mehta, Neil, Branch, Andrea, Pillai, Anjana, Hoteit, Maarouf, Volk, Michael, Odewole, Mobolaji, Scaglione, Steven, Guy, Jennifer, Said, Adnan, Feld, Jordan J, John, Binu V, Frenette, Catherine, Mantry, Parvez, Rangnekar, Amol S, Oloruntoba, Omobonike, Leise, Michael, Jou, Janice H, Bhamidimarri, Kalyan Ram, Kulik, Laura, Tran, Tram, Samant, Hrishikesh, Dhanasekaran, Renumathy, Duarte-Rojo, Andres, Salgia, Reena, Eswaran, Sheila, Jalal, Prasun, Flores, Avegail, Satapathy, Sanjaya K, Wong, Robert, Huang, Annsa, Misra, Suresh, Schwartz, Myron, Mitrani, Robert, Nakka, Sasank, Noureddine, Wassim, Ho, Chanda, Konjeti, Venkata R, Dao, Alexander, Nelson, Kevin, Delarosa, Kelly, Rahim, Usman, Mavuram, Meher, Xie, Jesse J, Murphy, Caitlin C, and Parikh, Neehar D

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Liver Disease, Emerging Infectious Diseases, Digestive Diseases, Rare Diseases, Hepatitis - C, Hepatitis, Chronic Liver Disease and Cirrhosis, Clinical Research, Liver Cancer, Cancer, Infectious Diseases, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Aged, Antiviral Agents, Canada, Carcinoma, Hepatocellular, Female, Hepatitis C, Chronic, Humans, Liver Neoplasms, Male, Middle Aged, Neoplasm Recurrence, Local, Retrospective Studies, Sustained Virologic Response, Time Factors, United States, Hepatitis C Virus, Recurrence, Direct-Acting Antiviral, Neurosciences, Paediatrics and Reproductive Medicine, Gastroenterology & Hepatology, Clinical sciences, Nutrition and dietetics
Abstract

Background & aimsThere is controversy over the effects of direct-acting antiviral (DAA) therapies for hepatitis C virus (HCV) infection on hepatocellular carcinoma (HCC) recurrence and tumor aggressiveness. We compared HCC recurrence patterns between DAA-treated and untreated HCV-infected patients who had achieved a complete response to HCC treatment in a North American cohort.MethodsWe conducted a retrospective cohort study of patients with HCV-related HCC with a complete response to resection, local ablation, transarterial chemo- or radioembolization, or radiation therapy from January 2013 through December 2017 at 31 health systems throughout the United States and Canada. Cox regression was used to examine the association between DAA therapy and time to recurrence after a complete response, with DAA therapy analyzed as a time-varying exposure. We also estimated the association between DAA therapy and risk of early HCC recurrence (defined as 365 days after complete response).ResultsOf 793 patients with HCV-associated HCC, 304 (38.3%) received DAA therapy and 489 (61.7%) were untreated. HCC recurred in 128 DAA-treated patients (42.1%; early recurrence in 52 patients) and 288 untreated patients (58.9%; early recurrence in 227 patients). DAA therapy was not associated with HCC recurrence (hazard ratio 0.90, 95% confidence interval 0.70-1.16) or early HCC recurrence (hazard ratio 0.96, 95% confidence interval 0.70-1.34) after we adjusted for study site, age, sex, Child-Pugh score, α-fetoprotein level, tumor burden, and HCC treatment modality. In DAA-treated and untreated patients, most recurrences were within the Milan criteria (74.2% vs 78.8%; P = .23). A larger proportion of DAA-treated than untreated patients received potentially curative HCC therapy for recurrent HCC (32.0% vs 24.6%) and achieved a complete or partial response (45.3% vs 41.0%) but this did not achieve statistical significance.ConclusionIn a large cohort of North American patients with complete response to HCC treatment, DAA therapy was not associated with increased overall or early HCC recurrence. HCC recurrence patterns, including treatment response, were similar in DAA-treated and untreated patients.

Published
2019

17. Development and validation of safety and efficacy-associated risk calculator for hepatocellular carcinoma in the elderly after resection (SEARCHER): A multi-institutional observational study

Author

Chen, Zi-Xiang, Schwartz, Myron, Gu, Li-Hui, Liang, Lei, Wang, Ping, Cescon, Matteo, Li, Ju-Dong, Liang, Ying-Jian, Pu, Jia-Le, Zhou, Ya-Hao, Wang, Hong, Gu, Wei-Min, Chen, Ting-Hao, Chen, Zhi-Yu, Wang, Ming-Da, Li, Chao, Zhang, Cheng-Wu, Pawlik, Timothy M., Lau, Wan Yee, Shen, Feng, Liu, Fu-Bao, and Yang, Tian

Published
2022
Full Text
View/download PDF

21. Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery

Author

Marron, Thomas U., Galsky, Matthew D., Taouli, Bachir, Fiel, Maria Isabel, Ward, Stephen, Kim, Edward, Yankelevitz, David, Doroshow, Deborah, Guttman-Yassky, Emma, Ungar, Benjamin, Mehandru, Saurabh, Golas, Benjamin J., Labow, Daniel, Sfakianos, John, Nair, Sujit S., Chakravarty, Dimple, Buckstein, Michael, Song, Xiaoyu, Kenigsberg, Effi, Gnjatic, Sacha, Brown, Brian D., Sparano, Joseph, Tewari, Ashutosh, Schwartz, Myron, Bhardwaj, Nina, and Merad, Miriam

Published
2022
Full Text
View/download PDF

24. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial

Author

Marron, Thomas U, Fiel, Maria Isabel, Hamon, Pauline, Fiaschi, Nathalie, Kim, Edward, Ward, Stephen C, Zhao, Zhen, Kim, Joel, Kennedy, Paul, Gunasekaran, Ganesh, Tabrizian, Parissa, Doroshow, Deborah, Legg, Meredith, Hammad, Ashley, Magen, Assaf, Kamphorst, Alice O, Shareef, Muhammed, Gupta, Namita T, Deering, Raquel, Wang, Wei, Wang, Fang, Thanigaimani, Pradeep, Mani, Jayakumar, Troncoso, Leanna, Tabachnikova, Alexandra, Chang, Christie, Akturk, Guray, Buckup, Mark, Hamel, Steven, Ioannou, Giorgio, Hennequin, Clotilde, Jamal, Hajra, Brown, Haley, Bonaccorso, Antoinette, Labow, Daniel, Sarpel, Umut, Rosenbloom, Talia, Sung, Max W, Kou, Baijun, Li, Siyu, Jankovic, Vladimir, James, Nicola, Hamon, Sara C, Cheung, Hung Kam, Sims, Jennifer S, Miller, Elizabeth, Bhardwaj, Nina, Thurston, Gavin, Lowy, Israel, Gnjatic, Sacha, Taouli, Bachir, Schwartz, Myron E, and Merad, Miriam

Published
2022
Full Text
View/download PDF

25. The Spatial Extracellular Proteomic Tumor Microenvironment Distinguishes Molecular Subtypes of Hepatocellular Carcinoma.

Author

Macdonald, Jade K., Taylor, Harrison B., Wang, Mengjun, Delacourt, Andrew, Edge, Christin, Lewin, David N., Kubota, Naoto, Fujiwara, Naoto, Rasha, Fahmida, Marquez, Cesia A., Ono, Atsushi, Oka, Shiro, Chayama, Kazuaki, Lewis, Sara, Taouli, Bachir, Schwartz, Myron, Fiel, M Isabel, Drake, Richard R., Hoshida, Yujin, and Mehta, Anand S.

Published
2024
Full Text
View/download PDF

33. Development and validation of an individualized prediction calculator of postoperative mortality within 6 months after surgical resection for hepatocellular carcinoma: an international multicenter study

Author

Liang, Lei, Quan, Bing, Wu, Han, Diao, Yong-Kang, Li, Jie, Chen, Ting-Hao, Zhang, Yao-Ming, Zhou, Ya-Hao, Zhang, Wan-Guang, Wang, Hong, Serenari, Matteo, Cescon, Matteo, Schwartz, Myron, Zeng, Yong-Yi, Liang, Ying-Jian, Jia, Hang-Dong, Xing, Hao, Li, Chao, Wang, Ming-Da, Yan, Wen-Tao, Chen, Wan-Yuan, Lau, Wan Yee, Zhang, Cheng-Wu, Pawlik, Timothy M., Huang, Dong-Sheng, Shen, Feng, and Yang, Tian

Published
2021
Full Text
View/download PDF

34. Cholangiocarcinoma, sequential chemotherapy, and prognostic tests.

Author

Bruckner, Howard W., De Jager, Robert, Knopf, Elisheva, Bassali, Fred, Book, Abe, Gurell, Daniel, Nghiem, Van, Schwartz, Myron, and Hirschfeld, Azriel

Subjects
PROGNOSTIC tests, CHOLANGIOCARCINOMA, CANCER chemotherapy, SURVIVAL rate, MITOMYCIN C
Abstract

Introduction: Routine blood tests are prognostic tests for patients with cholangiocarcinoma. New drug regimens may produce a median overall survival of 2 years or more. Methods: This single practice, IRB-approved, phase II trial examines prognostic tests, Kaplan-Meier survival, and univariate Cox regression analyses. Eligibility requires: intent-to-treat; signed consent; advanced measurable intrahepatic cholangiocarcinoma, with or without resistance to the test drugs; any adult age; performance status 0-2; and expected survival of = 6 weeks. Biweekly treatment, with 1/3 of standard dosages in mg/M2, includes: Gemcitabine 500; 5-Fluorouracil 1200 over 24 hours; Leucovorin 180; Irinotecan 80; and on day 2, Oxaliplatin 40. On progression, drugs are added on day 2: first, Docetaxel 25 precedes Oxaliplatin, with or without Mitomycin C 6 after Oxaliplatin. The next sequential additions are day 1, Cetuximab 400 total mg, then 200 mg weekly, and then Bevacizumab 10 mg/kg is substituted for Cetuximab (FDA IND# 119005). Results: For 35 patients, 19 with 1-2 lines of prior therapy, resistant tumors, and 16 no prior therapy, survival at 24-months is = 72 and = 58%, respectively. For 14 patients aged = 70 years, = 63% survive 24 months, P = 0.28. Validated tests that predict = 6-month survivals find median survival times of 17-months through > 2-years when compared to patients with favorable tests: Neutrophils lymphocyte ratio > 3.0, HR = 6.54, P < 6.4x10-3; absolute neutrophil count > 8000/ml, HR = 4.95, P < 6.5x10-3; serum albumin < 3.5 g/dl, HR = 4.10, P < 0.03; and lymphocyte monocyte ratio< 2.1, HR = 1.6, P = 0.50. Overall, the 76 (60-90)% of patients with 0-2 out of 4 high risk tests survive = 24 months, (P = 7.1x10-3). Treatments produce neither hospitalization, neutropenic fever, severe enteritis, nor severe neuropathies. Conclusion: Two-year survival is replicable and predictable. Findings warrant phase III validation tests of sequential regimens, re-challenge with recombination, low dosages, and blood tests that are associated with lethal mechanisms that impair response and survival. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus– and Hepatitis C Virus–Related Hepatocellular Carcinoma

Author

Huang, Daniel Q., primary, Hoang, Joseph K., additional, Kamal, Rubayet, additional, Tsai, Pei-Chien, additional, Toyoda, Hidenori, additional, Yeh, Ming-Lun, additional, Yasuda, Satoshi, additional, Leong, Jennifer, additional, Maeda, Mayumi, additional, Huang, Chung-Feng, additional, Won Jun, Dae, additional, Ishigami, Masatoshi, additional, Tanaka, Yasuhito, additional, Uojima, Haruki, additional, Ogawa, Eiichi, additional, Abe, Hiroshi, additional, Hsu, Yao-Chun, additional, Tseng, Cheng-Hao, additional, Alsudaney, Manaf, additional, Yang, Ju Dong, additional, Yoshimaru, Yoko, additional, Suzuki, Takanori, additional, Liu, Joanne K., additional, Landis, Charles, additional, Dai, Chia-Yen, additional, Huang, Jee-Fu, additional, Chuang, Wan-Long, additional, Schwartz, Myron, additional, Dan, Yock Young, additional, Esquivel, Carlos, additional, Bonham, Andrew, additional, Yu, Ming-Lung, additional, and Nguyen, Mindie H., additional

Published
2024
Full Text
View/download PDF

37. Racial and ethnic disparities in untreated patients with hepatitis C virus‐related hepatocellular carcinoma but not in those with sustained virologic response

Author

Park, Jung Eun, primary, Nguyen, Vy H., additional, Tsai, Pei‐Chien, additional, Toyoda, Hidenori, additional, Leong, Jennifer, additional, Guy, Jennifer E., additional, Yeh, Ming‐Lun, additional, Huang, Chung‐Feng, additional, Yasuda, Satoshi, additional, Abe, Hiroshi, additional, Hsu, Yao‐Chun, additional, Tseng, Cheng‐Hao, additional, Liu, Joanne, additional, Chen, Yao‐Li, additional, Lin, Ping‐Yi, additional, Jun, Dae Won, additional, Yoshimaru, Yoko, additional, Ogawa, Eiichi, additional, Ishigami, Masatoshi, additional, Enomoto, Masaru, additional, Tamori, Akihiro, additional, Uojima, Haruki, additional, Wang, Xiao Zhong, additional, Xu, Qiang, additional, Takahashi, Hirokazu, additional, Eguchi, Yuichiro, additional, Inoue, Kaori, additional, Huang, Daniel Q., additional, Zhao, Wen Jing, additional, Chuang, Wan‐Long, additional, Dai, Chia‐Yen, additional, Huang, Jee‐Fu, additional, Barnett, Scott, additional, Maeda, Mayumi, additional, Cheung, Ramsey, additional, Landis, Charles, additional, Tanaka, Yasuhito, additional, Roberts, Lewis R., additional, Schwartz, Myron E., additional, Kumada, Takashi, additional, Yu, Ming‐Lung, additional, and Nguyen, Mindie H., additional

Published
2024
Full Text
View/download PDF

39. Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma

Author

Finkin, Shlomi, Yuan, Detian, Stein, Ilan, Taniguchi, Koji, Weber, Achim, Unger, Kristian, Browning, Jeffrey L, Goossens, Nicolas, Nakagawa, Shigeki, Gunasekaran, Ganesh, Schwartz, Myron E, Kobayashi, Masahiro, Kumada, Hiromitsu, Berger, Michael, Pappo, Orit, Rajewsky, Klaus, Hoshida, Yujin, Karin, Michael, Heikenwalder, Mathias, Ben-Neriah, Yinon, and Pikarsky, Eli

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Liver Disease, Rare Diseases, Liver Cancer, Cancer, Stem Cell Research, Digestive Diseases, 2.1 Biological and endogenous factors, Aetiology, Adaptive Immunity, Animals, Carcinoma, Hepatocellular, Comparative Genomic Hybridization, Cytokines, Disease Models, Animal, Hepatocytes, Humans, I-kappa B Kinase, Immunity, Innate, Immunoblotting, In Situ Hybridization, Liver Neoplasms, Lymphoid Tissue, Mice, Inbred C57BL, Mice, Knockout, Mice, Transgenic, NF-kappa B, Neoplastic Stem Cells, Reverse Transcriptase Polymerase Chain Reaction, Stem Cell Niche, T-Lymphocytes, Transcriptome, Biochemistry and cell biology
Abstract

Ectopic lymphoid-like structures (ELSs) are often observed in cancer, yet their function is obscure. Although ELSs signify good prognosis in certain malignancies, we found that hepatic ELSs indicated poor prognosis for hepatocellular carcinoma (HCC). We studied an HCC mouse model that displayed abundant ELSs and found that they constituted immunopathological microniches wherein malignant hepatocyte progenitor cells appeared and thrived in a complex cellular and cytokine milieu until gaining self-sufficiency. The egress of progenitor cells and tumor formation were associated with the autocrine production of cytokines previously provided by the niche. ELSs developed via cooperation between the innate immune system and adaptive immune system, an event facilitated by activation of the transcription factor NF-κB and abolished by depletion of T cells. Such aberrant immunological foci might represent new targets for cancer therapy.

Published
2015

40. A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery

Author

Crouchet, Emilie, Bandiera, Simonetta, Fujiwara, Naoto, Li, Shen, El Saghire, Hussein, Fernández-Vaquero, Mirian, Riedl, Tobias, Sun, Xiaochen, Hirschfield, Hadassa, Jühling, Frank, Zhu, Shijia, Roehlen, Natascha, Ponsolles, Clara, Heydmann, Laura, Saviano, Antonio, Qian, Tongqi, Venkatesh, Anu, Lupberger, Joachim, Verrier, Eloi R., Sojoodi, Mozhdeh, Oudot, Marine A., Duong, François H. T., Masia, Ricard, Wei, Lan, Thumann, Christine, Durand, Sarah C., González-Motos, Victor, Heide, Danijela, Hetzer, Jenny, Nakagawa, Shigeki, Ono, Atsushi, Song, Won-Min, Higashi, Takaaki, Sanchez, Roberto, Kim, Rosa S., Bian, C. Billie, Kiani, Karun, Croonenborghs, Tom, Subramanian, Aravind, Chung, Raymond T., Straub, Beate K., Schuppan, Detlef, Ankavay, Maliki, Cocquerel, Laurence, Schaeffer, Evelyne, Goossens, Nicolas, Koh, Anna P., Mahajan, Milind, Nair, Venugopalan D., Gunasekaran, Ganesh, Schwartz, Myron E., Bardeesy, Nabeel, Shalek, Alex K., Rozenblatt-Rosen, Orit, Regev, Aviv, Felli, Emanuele, Pessaux, Patrick, Tanabe, Kenneth K., Heikenwälder, Mathias, Schuster, Catherine, Pochet, Nathalie, Zeisel, Mirjam B., Fuchs, Bryan C., Hoshida, Yujin, and Baumert, Thomas F.

Published
2021
Full Text
View/download PDF

42. Author Correction: Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery

Author

Marron, Thomas U., Galsky, Matthew D., Taouli, Bachir, Fiel, Maria Isabel, Ward, Stephen, Kim, Edward, Yankelevitz, David, Doroshow, Deborah, Guttman-Yassky, Emma, Ungar, Benjamin, Mehandru, Saurabh, Golas, Benjamin J., Labow, Daniel, Sfakianos, John, Nair, Sujit S., Chakravarty, Dimple, Buckstein, Michael, Song, Xiaoyu, Kenigsberg, Effi, Gnjatic, Sacha, Brown, Brian D., Sparano, Joseph, Tewari, Ashutosh, Schwartz, Myron, Bhardwaj, Nina, and Merad, Miriam

Published
2022
Full Text
View/download PDF

46. Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy.

Author

Chen, Hui-Ming, Ma, Ge, Gildener-Leapman, Neil, Eisenstein, Samuel, Coakley, Brian, Ozao, Junko, Mandeli, John, Divino, Celia, Schwartz, Myron, Sung, Max, Ferris, Robert, Kao, Johnny, Wang, Lu-Hai, Pan, Ping-Ying, Ko, Eric, and Chen, Shu-Hsia

Subjects
Antineoplastic Agents, CD11b Antigen, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Cell Proliferation, Cell Survival, Disease Progression, Flow Cytometry, Humans, Immune System, Immunosuppressive Agents, Indoles, Leukocytes, Mononuclear, Monocytes, Myeloid Cells, Neoplasm Metastasis, Neoplasms, Phosphorylation, Pyrroles, Radiosurgery, STAT3 Transcription Factor, Sialic Acid Binding Ig-like Lectin 3, Sunitinib, Treatment Outcome
Abstract

PURPOSE: The clinical effects of sunitinib on human myeloid-derived suppressor cell (MDSC) subsets and correlation of the T-cell-mediated immune responses and clinical outcomes in patients with oligometastases treated by stereotactic body radiotherapy (SBRT) have been evaluated. EXPERIMENTAL DESIGN: The numbers of granulocytic and monocytic MDSC subsets, effector T cells, and regulatory T cells in the peripheral blood were evaluated pre- and post-sunitinib treatment and concurrent with SBRT. Correlations between MDSC, Treg, and T-cell responses and clinical outcomes were analyzed. RESULTS: Patients with oligometastases of various cancer types had elevated granulocytic MDSC and certain subsets of monocytic MDSC population. Sunitinib treatment resulted in a significant reduction in monocytic MDSC, phosphorylated STAT3, and arginase levels in monocytic MDSC (CD33(+)CD14(+)CD16(+)), and an increase in T-cell proliferative activity in cancer patients. Interestingly, the effects of sunitinib on reducing the accumulation and immune-suppressive function of MDSC were significantly correlated with Treg reduction, in responders but not in nonresponding patients. SBRT synergized the therapeutic effects of sunitinib, especially as related to decreased numbers of monocytic MDSC, Treg, and B cells, and augmented Tbet expression in primary CD4 and CD8 T cells. These effects were not observed in patients receiving radiation therapy alone. Most interestingly, the responders, defined by sunitinib-mediated reduction in CD33(+)CD11b(+) myeloid cell populations, tend to exhibit improved progression-free survival and cause-specific survival. CONCLUSIONS: Sunitinib treatment increased the efficacy of SBRT in patients with oligometastases by reversing MDSC and Treg-mediated immune suppression and may enhance cancer immune therapy to prevent tumor recurrence post-SBRT.

Published
2015

48. Prognostic significance of nodular number in patients undergoing hepatectomy of intermediate-stage hepatocellular carcinoma.

Author

Fan, Zhong-Qi, Serenari, Matteo, Lv, Xing, Schwartz, Myron, Qiu, Wei, Pawlik, Timothy M, Chen, Zhong, Zhou, Ya-Hao, Wang, Xian-Ming, Chen, Ting-Hao, Li, Jie, Zhang, Cheng-Wu, Wang, Hong, Zhang, Yao-Ming, Gu, Wei-Min, Liang, Ying-Jian, Diao, Yong-Kang, Yao, Lan-Qing, Li, Chao, and Cescon, Matteo

Subjects
HEPATOCELLULAR carcinoma, CHEMOEMBOLIZATION, HEPATECTOMY, SURGICAL blood loss, PATIENT selection, SURGERY
Abstract

This article, published in the British Journal of Surgery, examines the importance of nodular number in predicting the prognosis of patients with intermediate-stage hepatocellular carcinoma (HCC) who undergo hepatectomy. The study, conducted at multiple hepatobiliary centers in China, Italy, and the USA, analyzed data from HCC patients who had undergone curative-intent hepatic resection between 2008 and 2018. The findings indicate that patients with three or more tumor nodules had lower overall survival and recurrence-free survival rates compared to those with two nodules. The study suggests that nodular number should be considered when predicting long-term prognosis after hepatic resection for intermediate-stage HCC. However, further research is needed to validate these findings. The study was supported by various funding sources and the authors have no conflicts of interest. [Extracted from the article]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results